Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Embrace Hydrogel Embolic System (HES) is an investigational, minimally invasive vascular embolization device developed for use in interventional radiology. It is designed to treat hypervascular tumors and control peripheral arterial bleeding by blocking blood flow within targeted vessels. The system consists of two liquid precursors—primarily water and polyethylene glycol (PEG)—that are simultaneously injected into blood vessels, where they rapidly solidify to form a soft hydrogel that fills the vessel lumen. This process achieves controlled, complete, and persistent embolization without the need for solvents or sizing to vessel diameter and eliminates the risk of catheter entrapment. Clinical studies have demonstrated technical success in embolizing both malignant and benign hypervascular tumors such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and angiomyolipoma (AML). Preclinical models also show efficacy in achieving hemostasis for various types of peripheral arterial bleeds[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Embrace Hydrogel Embolic System.